Decipher Genomic Classifier Shows Promise for Predicting Prostate Cancer Treatment Outcomes
核心洞察
Two recent studies validate the Decipher (搜索) genomic classifier as a strong predictor of treatment failure in prostate cancer patients, with particularly robust performance in African American men.
The VANDAAM study demonstrated that the genomic classifier achieved an area under the curve of 0.889 for predicting 2-year biochemical recurrence in African American patients.
A separate analysis found that patients with high-risk genomic classifier scores had significantly higher rates of treatment failure after focal cryotherapy compared to low-risk patients.
Two recent studies have provided compelling evidence that the Decipher (搜索) genomic classifier can effectively predict treatment outcomes in prostate cancer patients, with particularly strong performance in African American men. The findings suggest this molecular test could help clinicians make more informed treatment decisions and better counsel patients about their risk of disease recurrence.
Strong Predictive Performance in Diverse Patient Population
The prospective VANDAAM study, published in the Journal of the National Comprehensive Cancer Network, evaluated 226 men with early-stage prostate cancer treated between 2016 and 2021. Of the 207 patients with completed test results and follow-up, 104 were African American and 103 were White, matched by CAPRA score. All patients received either surgery or definitive radiotherapy with or without short-term androgen deprivation therapy.
In the overall cohort, the genomic classifier achieved an area under the curve (AUC) of 0.783, which increased to 0.814 after adjusting for clinicopathologic variables. Patients in the high-risk genomic classifier category demonstrated a 6.6-fold increase in the odds of experiencing 2-year biochemical recurrence compared with those in the low-risk category (OR, 6.6; 95% CI, 1.61 to 26.91; P = .008).
Exceptional Performance in African American Patients
The genomic classifier showed particularly impressive results in African American patients, yielding an AUC of 0.889 for identifying 2-year biochemical recurrence. This performance improved further to 0.984 after adjusting for clinicopathologic variables.
"This substantial improvement underscores the added value of combining genomic and clinical information to enhance predictive accuracy for 2-year BCR outcomes among African-American patients," the authors noted.
African American patients in the high-risk category demonstrated a striking 21.56-fold increase in the odds of 2-year biochemical recurrence compared with those in the low-risk category (OR, 21.56; 95% CI, 1.16 to 400.74; P = .04).
Focal Therapy Applications
A separate post-hoc analysis of a phase 2 trial, reported in JCO Precision Oncology, examined the genomic classifier's utility in predicting focal therapy outcomes. The study assessed 108 patients with unilateral grade group 2 to 4 prostate cancer who underwent hemigland cryoablation between 2017 and 2021.
The median genomic classifier score in this cohort was 0.34, with 66% of patients classified as low-risk (score less than 0.45). Treatment failure at 6-month biopsy occurred in 46% of patients in the high-risk group versus 21% in the low-risk group (OR, 2.61; 95% CI, 1.05 to 6.51; P = .04). This difference remained statistically significant at 18 months, with failure rates of 76% versus 44% (OR, 3.58; 95% CI, 1.37 to 9.36; P = .009).
Clinical Implications and Future Directions
"One of the most important messages from this study is that genomic risk information adds useful detail on top of the tools clinicians already use," said principal investigator Kosj Yamoah, MD, PhD, chair of the Radiation Oncology Department at Moffitt Cancer Center. "For African American men with early prostate cancer, this test helped separate a small group with rapid recurrence from the large group who remained cancer free at 2 years."
The focal therapy study authors concluded that while focal therapy may offer oncologic benefits with fewer adverse effects, "the rate of treatment failure remains appreciable. A genomic classifier based on biopsy tissue identified patients at an increased risk of treatment failure, beyond clinicopathologic variables."
Both studies emphasize the potential for genomic testing to improve treatment selection and patient counseling. As Yamoah noted, "These data support using genomic testing earlier in care to better match African American patients with the treatment intensity and type that fit the biology of their tumor. It is one practical step toward narrowing long-standing differences in prostate cancer outcomes."
The researchers acknowledge that further validation is needed, particularly given the limited number of biochemical recurrence events in some patient subgroups. However, these findings represent important steps toward more personalized prostate cancer care.